APVO Aptevo Therapeutics Inc.
USHealthcareAs of 2026-08-24
Why APVO matters now
Aptevo Therapeutics Inc. (APVO) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.41 with -10.07% on the session and $5.3M in market capitalization; recent performance reads 1-month +4.94% and YTD -50.48%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-6.7M, and EPS of $-6.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -264.2%.
The latest indexable market news headline is "Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Janatpour Mary Jo filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.43
P/S
0.00
EV/EBITDA
-0.00
DCF Value
$5,118.26
FCF Yield
-264.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-198.5%
ROA
-131.9%
ROIC
-166.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-6.7M | $-6.41 |
| Q4 2025 | $0.00 | $-5.8M | $-159.33 |
| FY 2025 | $0.00 | $-26.0M | $-87.27 |
| Q3 2025 | $0.00 | $-7.5M | $-40.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.69
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.